<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To investigate the expression change of human leukocyte antigen (HLA) class I on human peripheral blood mononuclear cells (PBMCs) at both <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels, and to evaluate its roles in the development of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: In the present study, 50 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, 35 patients with benign colorectal lesion and 42 healthy volunteers were enrolled </plain></SENT>
<SENT sid="2" pm="."><plain>Expression levels of HLA class I <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein were determined using real-time quantitative reverse transcription PCR (RT-PCR) and flow cytometry analysis, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The expression levels of HLA class I <z:chebi fb="2" ids="33699">mRNA</z:chebi> and proteins were not influenced by age and gender </plain></SENT>
<SENT sid="4" pm="."><plain>The relative ratios of HLA class I <z:chebi fb="2" ids="33699">mRNA</z:chebi> were 0.99±0.27 in healthy controls, 0.76±0.19 in benign patients, and 0.48±0.21 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>Mean fluorescence intensities of HLA class I were 145.58±38.14 in healthy controls, 102.05±35.98 in benign patients and 87.44±34.01 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="6" pm="."><plain>HLA class I on PBMCs was significantly down-regulated at both <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels in patients with stage III and IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> also showed a decreased HLA class I expression at protein level </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: HLA class I expressions on PBMCs are associated with staging of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Monitoring the expression of HLA class I on PBMCs may provide useful information for diagnosis and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> judgement of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>